Search Results

SimBioSys announced today it has entered a strategic collaboration with UT Southwestern to support the expansion of its PhenoScope platform, the company’s proprietary multi-modal data analysis platform which generates novel insights for discovery and clinical development, including unique spatial biophysical insights in 4-dimension space.

RenovoRx, Inc today announced that the University of Texas (UT) Southwestern Medical Center is now enrolling pancreatic cancer patients in the open label, randomized Phase III TIGeR-PaC clinical trial.

BerGenBio ASA, a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, announced that it has entered into a clinical trial agreement with the Mays Cancer Center at The University of Texas Health Science Center at San Antonio and Swedish Orphan Biovitrum AB, a specialized international biopharmaceutical company.

Watertown Regional Medical Center and Healthcare Outcomes Performance Company have joined forces to provide top-tier orthopedic and spine care for patients.

Actinium Pharmaceuticals, Inc. announced it will host a KOL call on Monday, May 20, 2024, at 8:00 AM ET to provide updates and highlight its recently announced clinical trial to study Iomab-ACT with a leading FDA approved CAR-T cell therapy at the University of Texas Southwestern.

Stereotaxis, a pioneer in surgical robotics for minimally invasive endovascular intervention, announces the successful treatment of the first heart rhythm patients by Penn Presbyterian Medical Center utilizing the advanced Genesis Robotic Magnetic Navigation System.

Alcanza Clinical Research, a mission-focused investigator site network, has acquired Innovation Medical Research Center, a multi-specialty clinical research center.

Actinium Pharmaceuticals, Inc. announced that the University of Texas Southwestern Medical Center will lead a clinical trial studying Actinium’s Iomab-ACT, a targeted radiotherapy conditioning agent prior to patients receiving an FDA approved commercial CAR T-cell therapy.

Ractigen Therapeutics announces a formal collaboration with University Medical Center Utrecht, affiliated with Utrecht University.

QT Imaging Holdings, Inc. is honored to partner with University of Oklahoma and OU Health Stephenson Cancer Center to advance and scale innovative research in medical imaging and to improve precision in cancer detection and treatment.